Acer Therapeutics (ACER) Receives Daily Media Sentiment Score of 0.01

Press coverage about Acer Therapeutics (NASDAQ:ACER) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Acer Therapeutics earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.0199660410953 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of research analysts have recently commented on ACER shares. ValuEngine raised shares of Acer Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. HC Wainwright set a $50.00 price objective on shares of Acer Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 4th.

Acer Therapeutics (ACER) opened at $19.02 on Wednesday. Acer Therapeutics has a 52-week low of $5.69 and a 52-week high of $22.63. The stock has a market cap of $134.68, a PE ratio of -3.31 and a beta of 2.24.

Acer Therapeutics (NASDAQ:ACER) last issued its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter. equities research analysts anticipate that Acer Therapeutics will post -1.48 earnings per share for the current fiscal year.

WARNING: This article was originally published by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/opexa-therapeutics-acer-receiving-somewhat-positive-media-coverage-study-shows/1822551.html.

About Acer Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Insider Buying and Selling by Quarter for Acer Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.